Neoadjuvant chemotherapy in advanced ovarian cancer: On what do we agree and disagree?

Affiliations

¹ University Hospital Leuven, Leuven Cancer Institute, Division of Gynecological Oncology, Department of Obstetrics and Gynecology, Leuven, Belgium European Union. Electronic address: Ignace.vergote@uzleuven.be.
² Kliniken Essen Mitte, Department of Gynecology & Gynecologic Oncology, Essen, Germany.
³ University Hospital Leuven, Leuven Cancer Institute, Division of Gynecological Oncology, Department of Obstetrics and Gynecology, Leuven, Belgium European Union.

Ignace Vergote et al. Gynecol Oncol. 2013 Jan.

. 2013 Jan;128(1):6-11.

doi: 10.1016/j.ygyno.2012.09.013. Epub 2012 Sep 21.

¹ University Hospital Leuven, Leuven Cancer Institute, Division of Gynecological Oncology, Department of Obstetrics and Gynecology, Leuven, Belgium European Union. Electronic address: Ignace.vergote@uzleuven.be.
² Kliniken Essen Mitte, Department of Gynecology & Gynecologic Oncology, Essen, Germany.
³ University Hospital Leuven, Leuven Cancer Institute, Division of Gynecological Oncology, Department of Obstetrics and Gynecology, Leuven, Belgium European Union.

No abstract available

MeSH terms